Placebo News and Research

RSS

Three effective treatments for childhood anxiety disorders found

Treatment that combines a certain type of psychotherapy with an antidepressant medication is most likely to help children with anxiety disorders, but each of the treatments alone are also effective, according to a new study funded by the National Institute's of Health's National Institute of Mental Health (NIMH) The study was published online Oct. 30, in the New England Journal of Medicine.

30 Oct 2008

Cancer requires support from immune system to develop, researchers report

Tumors that grow around nerves in a rare genetic disease need cooperation from cells from the immune system in order to grow, reports a team of scientists, including researchers from UT Southwestern Medical Center.

30 Oct 2008

Drinking milk to ease milk allergy?

Giving children with milk allergies increasingly higher doses of milk over time may ease, and even help them completely overcome, their allergic reactions, according to the results of a study led by the Johns Hopkins Children's Center and conducted jointly with Duke University.

29 Oct 2008

Phenomix starts phase 1a trial of hepatitis C protease inhibitor

Phenomix Corporation today announced it has begun administering subjects in a Phase 1a clinical trial of PHX1766, the company's internally discovered, orally available NS3/4A protease inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.

28 Oct 2008

Selenium and vitamin E supplements do not prevent prostate cancer

Initial, independent review of study data from the Selenium and Vitamin E Cancer Prevention Trial (SELECT), funded by the National Cancer Institute (NCI) and other institutes that comprise the National Institutes of Health shows that selenium and vitamin E supplements, taken either alone or together, did not prevent prostate cancer.

28 Oct 2008

Vitamin E and selenium do not prevent prostate cancer

A major study on whether vitamin E and selenium prevent prostate cancer has been stopped because the supplements are not effective and also because there is a suspicion of a risk.

28 Oct 2008

Expensive new diabetes drugs don't necessarily produce better outcomes

The annual cost of prescription diabetes drugs nearly doubled to $12.5 billion between 2001 and 2007, according to a study by researchers at the Stanford University School of Medicine and the University of Chicago. The researchers say the findings raise questions about whether the higher cost actually translates into improved care and better outcomes.

28 Oct 2008

Nanocort demonstrates safety and good response in phase I/II trial for rheumatoid arthritis

Galapagos NV has announced that Nanocort has demonstrated safety as well as a faster and more pronounced decrease in rheumatoid arthritis disease symptoms compared to reference medication.

27 Oct 2008

Bisphosphonates for osteoporosis increase risk for heart problems

People who take bisphosphonates for osteoporosis may be at risk for serious atrial fibrillation (AF), or irregular heartbeats, according to a new study.

27 Oct 2008

NanoBio demonstrates new topical approach to treating nail fungus that circumvents problems with current therapy

A novel topical therapy for nail fungus, NB-002, has demonstrated a new topical approach to healing nail fungus by penetrating skin pores and diffusing through the skin that surrounds the entire nail plate, according to a study conducted by NanoBio Corporation.

27 Oct 2008

New gout drug offers hope for those who have exhausted treatment options

Researchers in the U.S. say a new drug effectively treats serious cases of gout - the drug called pegloticase mimics a blood-clearing enzyme missing in humans and helps remove the build up in uric acid, which causes the painful, needle-like crystals to collect around fingers, toes and other joints.

27 Oct 2008

New obesity drug Tesofensine may have huge potential

According to trials, a new obesity drug, Tesofensine, which may be launched on the world market in a few years, can produce weight loss twice that of currently approved obesity drugs. The Danish company Neurosearch and a number of researchers at the Faculty of Life Sciences at University of Copenhagen are behind the promising findings.

23 Oct 2008

CytoDyn files new IND for Cytolin

CytoDyn, Inc. has filed a new IND for a study to reconfirm dose ranging and to "prove the principle" with a randomized, double-blind placebo controlled study of Cytolin, the Company's first-in-class drug for treating HIV/AIDS. This comes 13 years after the first IND was issued for the drug.

22 Oct 2008

Addex Parkinson's product progressing in early clinical trials

Addex Pharmaceuticals has announced that it has completed the first part of a two-part Phase I clinical trial to evaluate the newly developed modified release formulation of ADX48621. ADX48621 is scheduled to start a Phase IIa proof of concept study for the treatment of levodopa associated dyskinesia in Parkinson's disease during the first half of 2009.

15 Oct 2008

High-dose vitamin B supplements do not slow cognitive decline in Alzheimer's

A clinical trial led by Paul S. Aisen, M.D., professor of neurosciences at the University of California, San Diego School of Medicine, showed that high-dose vitamin B supplements did not slow the rate of cognitive decline in patients with mild to moderate Alzheimer disease.

14 Oct 2008

More effective treatment found for convergence insufficiency, a childhood vision disorder

Scientists have found a more effective treatment for a common childhood eye muscle coordination problem called convergence insufficiency (CI). For words on a page to appear in focus a child's eyes must turn inward, or converge. In CI, the eyes do not converge easily, and as a result, additional muscular effort must be used to make the eyes turn in.

14 Oct 2008

Steroids aid recovery from pneumonia, UT Southwestern researchers say

Adding corticosteroids to traditional antimicrobial therapy might help people with pneumonia recover more quickly than with antibiotics alone, UT Southwestern Medical Center scientists have found.

14 Oct 2008

Best treatment determined for convergence insufficiency in children

Mayo Clinic researchers, as part of a nine-site study, helped discover the best of three currently-used treatments for convergence insufficiency in children. Convergence refers to the natural ability of the eyes to focus and align while viewing objects up close.

14 Oct 2008

Vioxx heart risks confirmed in long-term study

The study, an analysis of people who took the arthritis drug carried out by Dr. Robert Bresalier of the M.D. Anderson Cancer Center at the University of Texas, has found Vioxx doubles the risk of strokes and heart attacks.

14 Oct 2008

Probiotics unlikely to relieve eczema symptoms

Australian scientists say they have found no evidence that probiotics can relieve the irritating symptoms of eczema and what is more they suggest they may sometimes cause infections and gut problems.

13 Oct 2008